Apellis Pharmaceuticals (APLS) Now Covered by Analysts at J P Morgan Chase & Co
Equities researchers at J P Morgan Chase & Co began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $31.00 price target on the stock. J P Morgan Chase & Co’s target price would indicate a potential upside of 121.43% from the stock’s previous close.
Apellis Pharmaceuticals (NASDAQ:APLS) traded down $0.02 during trading hours on Monday, hitting $14.00. 323,920 shares of the stock were exchanged, compared to its average volume of 111,537. Apellis Pharmaceuticals has a twelve month low of $12.45 and a twelve month high of $15.41.
In related news, major shareholder Global Strategic Fund I. Venbio bought 127,515 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $1,785,210.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/04/apellis-pharmaceuticals-apls-now-covered-by-analysts-at-j-p-morgan-chase-co.html.
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.